ExpreS2ion announced late yesterday that it has obtained a guarantee undertaking of approximately SEK 19.3m, equal to around 60% of the maximum proceeds from the ongoing TO 13 warrant programme, and CEO Bent U. Frandsen states that the undertakings secure the capital to advance ES2B-C001 through its primary Phase I read-out.

The company has separately entered into a put option agreement with Alumni Capital giving access to up to SEK 50m in committed equity financing.

Both are conditional on an extraordinary general meeting on or around 1 October 2026 approving a new issue authorisation.

In our Q2 2026 investment case, published 7 September, we framed the near-term question as funding rather than science, and specifically flagged that with the share below the SEK 1.60 TO 13 floor, take-up was uncertain. Today's announcement removes most of that uncertainty on the amount, while confirming that the dilution associated with the warrant programme now happens more or less regardless of what warrant holders choose to do.

The mechanics

The 20,218,750 TO 13 warrants carry an exercise price of SEK 1.60, the quota value, and are exercisable from 7 to 21 September. Full exercise would raise approximately SEK 32.4m. With the share closing at SEK 1.25 on 14 September, the exercise price sits around 28% above the market, so voluntary take-up is unlikely to be meaningful. If less than roughly 60% of the warrants are exercised, the board intends to resolve on a directed issue to the guarantor at SEK 1.60 after the exercise period ends, using the authorisation the EGM is asked to grant. The guarantee undertaking comes from Vator Securities, which has contracted with lead investors Alumni Capital and Tellus Equity AB alongside committed shareholders and external investors.

What the guarantee costs

The compensation is 10% of the guaranteed amount in cash and 30% in newly issued shares. That headline looks heavy, but the consideration shares are issued at SEK 1.60, a premium of approximately 28% to the close, which is what brings the board's stated effective fee down to around 12% measured against market.

In our view that is within the range seen in Nordic small-cap biotech guarantees in the current market, and the board's argument that the structure is less dilutive than a rights issue on current terms is reasonable.

It is worth noting the other side of it: raising SEK 19.3m gross through the guarantee route costs up to 15.7m new shares, whereas SEK 32.4m through voluntary exercise would cost 20.2m shares. Per krona raised, exercise is the cheaper outcome for existing holders, which is one reason the take-up level still matters even though the amount is now largely secured.

Dilution and the implied model update

The directed issue can add up to approximately 12,092,091 shares and the compensation issue up to approximately 3,627,627 shares, together around 15.7m against 23,748,983 outstanding, or roughly 66%. Holding all other model assumptions unchanged and using the SEK 1.25 close, this would lift our base-case model-implied probability of success from around 1.0% to roughly 1.6%, against the approximately 1.9% we published for full warrant exercise at a SEK 1.345 share price.

This is our own indicative arithmetic rather than a model update. The central observation from the Q2 case is unchanged: even after the raise, market capitalisation remains close to or below reported cash, so enterprise value stays around or below zero and the market continues to ascribe very little to the pipeline and platform, well below the approximately 5% oncology benchmark.

The Alumni Capital facility

The put option agreement is optionality rather than near-term capital. The floor price of SEK 4.00 is more than three times the current share price, so the facility cannot be drawn unless the share re-rates substantially, and drawdowns are at the company's sole discretion with a no short selling undertaking from the investor.

The cost is real and payable at the Effective Date, which falls between mid-March 2027 and mid-June 2027 on the stated definition: a commitment fee of 5% of the SEK 50m, payable in shares or cash at the company's discretion, plus 500,000 shares valued at approximately SEK 625k on yesterday's close. Investors should read this as a standby facility priced against a materially higher share price, not as a solution to the Phase II funding question.

Use of proceeds and what remains open

The stated first priority is completing the Phase I study through its primary read-out, covering safety, immunogenicity and translational analyses assessing early evidence of anti-tumour activity, ahead of continued maintenance dosing.

Management adds that securing a strategic partnership for ES2B-C001 remains the primary objective, and that the financings are intended to allow the company to pursue that from a position of strength. We note the company has not published a runway statement, and we do not extrapolate one here.

For context, cash was SEK 34.4m at 30 June and operating cash outflow was SEK 12.5m in Q2. The second stated priority, strengthening the financial position in ongoing and/or planned licensing negotiations with international oncology players, is a slightly firmer formulation than the general partnering language used previously, although no counterparty or process detail is given.

The guarantee and the facility are both conditional on the EGM resolving in line with the board's proposal, which requires a two-thirds majority of both votes cast and shares represented. The record date is 23 September and notifications and postal votes are due by 25 September. Warrant holders must decide whether to exercise by 21 September, before the EGM outcome is known.

Beyond that, the funding route into Phase II still runs through a partnership that is not secured, Phase II initiation is guided to H2 2027, and the end-2026 Phase I primary read-out remains the principal re-rating trigger in our case.

HC Andersen Capital receives payment from ExpreS2ion Biotech Holding AB for a Digital IR/Corporate Visibility subscription agreement. Michael Friis, 08:05, 15 September 2026.